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Obesity, diabetes, and metabolic syndromes are increasingly recognized as health concerns worldwide. Overnutrition and insulin
resistance are the major causes of diabetic hyperglycemia and hyperlipidemia in humans. Studies in the past decade provide evi-
dence that bile acids are not just biologicaldetergents facilitatinggut nutrient absorption, but also important metabolic regulators
of glucose and lipid homeostasis.Pharmacologicalalteration of bile acid metabolism or bile acid signalingpathways such as using
bile acid receptor agonists or bile acid binding resins may be a promising therapeutic strategy for the treatment of obesity and
diabetes. On the other hand, bile acid signaling is complex, and the molecular mechanisms mediating the bile acid eﬀects are still
not completely understood. This paper will summarize recent advances in our understanding of bile acid signaling in regulation
of glucose and lipid metabolism, and the potentials of developing novel therapeutic strategies that target bile acid metabolism for
the treatment of metabolic disorders.
1.Introduction
Bile acids are produced only in the liver as the end products
of cholesterol catabolism [1, 2]. In addition to the classic
function of bile acids in facilitating hepatobiliary secretion
of endogenous metabolites and xenobiotics and intestine
absorption of lipophilic nutrients, bile acids also play equal-
ly important roles in controlling the metabolism of glu-
cose and lipids in the enterohepatic system, and energy ex-
penditure in peripheral tissues [3, 4]. Because of such a close
association between bile acid signaling and metabolic home-
ostasis, targeting bile acid metabolism by using bile acid re-
ceptor agonists or bile acid-binding resins have proven to
be eﬀective in improving lipid and glucose homeostasis in
obesity and diabetes [5]. Furthermore, stimulating de novo
bileacid synthesis prevented,whereas, disruption of bile acid
signaling caused insulin resistance and dyslipidemia in mice,
indicating that impaired bile acid homeostasis may likely
contribute to the pathogenesis of metabolic disorders [6–
9]. This paper will summarize recent advances in our un-
derstanding of bile acid signaling regulation of glucose and
lipidmetabolismand thepotentialsofdevelopingnovelther-
apeutic strategies that target bile acid metabolism for the
treatment of metabolic disorders.
2.Bile AcidSynthesis
Bile acids are the end product of cholesterol catabolism in
the liver [1, 10–12]. In humans, the bile acid pool consists of
primary bile acids cholic acid (CA), chenodeoxycholic acid
(CDCA), secondary bile acids deoxycholic acid (DCA), and
lithocholic acid (LCA). Primary bile acids are synthesized
from cholesterol through two general pathways, the classic
pathwayandthealternativepathway.Secondarybileacidsare
derived from primary bile acids in the intestine by bacterial
enzymes. Enzymes that catalyze these multistep reactions are
located in the endoplasmic reticulum, mitochondria, cyto-
sol, and peroxisomes. In humans, the classic pathway is con-
sideredasthemajorbileacidsynthetic pathway(accountsfor
more than 90% of total bile acid production) and produces
CA and CDCA in approximately equal amounts. Cholesterol
7α-hydroxylase (CYP7A1), a microsomal cytochrome p450
enzyme, catalyzes the ﬁrst and rate-limiting step in the
classic pathway [13]. The intermediate product in the clas-
sic pathway 7α-hydroxy-4-cholestene-3-one serves as the
common precursor for both CA and CDCA. 7α-hydroxy-4-
cholestene-3-one can be hydroxylated at C-12 position by
microsomal sterol 12α-hydroxylase (CYP8B1), followed up
by several reactions including mitochondrial 27-hydroxylase2 Journal of Lipids
(CYP27A1)to cleavea 3-carbonunitand eventuallyconvert-
ed to CA. Without 12α-hydroxylation, 7α-hydroxy-4-choles-
tene-3-one is converted to CDCA. Thus, CYP7A1 controls
the overall rate of bile acid production, while CYP8B1 con-
trols the CA: CDCA ratio in the bile acid pool. The alter-
native pathway (also known as acidic pathway), which is
thought to account for less than 10% of the total bile acid
synthesis in humans, mainly produces CDCA. CYP27A1
catalyzes hydroxylation of cholesterol to 27-hydroxycholes-
terol and then 3β-dihydroxy-5-cholestionic acid [14]. Oxys-
terol 7α-hydroxylase (CYP7B1) then catalyzes the hydroxy-
lation reaction at C-7 position of these two intermediates,
which are subsequently converted to CDCA by the same
enzymes in the classic pathway.
3.Bile Acid Transportand
EnterohepaticCirculation
Bile acids, once produced in the liver, are transported across
the canalicular membrane of the hepatocytes into the bile
and stored in the gallbladder. After each meal, gallbladder
bile acids are released into the intestinal tract, eﬃciently
reabsorbed in the ileum, and transported back to the liver
via portal blood for reexcretion into the bile. This process
is referred to as enterohepatic circulation of bile acids [10]
(Figure 1). Bile acid transporters play important roles in this
transport process [15]. The biliary excretion of bile acids is
the major driving force of bile ﬂow. The bile acid pool size
is deﬁned as the total amount of bile acids circulating in the
enterohepatic circulation. In humans, bile acid pool consists
of CA, CDCA, and DCA in an approximate 40:40:20
ratio. In mice, the majority of the CDCA is converted into
muricholic acids (MCAs), which are highly soluble and less
toxic.
Hepatocytes are polarized epithelial cells with basolateral
(sinusoidal) and apical (canalicular) membrane domains.
Hepatocytes take up bile acids through the basolateral
membrane, which is in direct contact with the portal blood
plasma, and excrete bile acid at the canalicular membrane
into the bile [16] .S i n c et h eb i l i a r yb i l ea c i d sc o n c e n t r a t i o n
is about 100- to 1000-fold higher in the bile than in the
hepatocytes, canalicular bile acid transport represents the
rate-limiting step in bile formation. Several members of the
ATP-binding cassette (ABC) transporter family are responsi-
ble for transporting bile acids and other organic compounds
across the canalicular membrane against their concentration
gradients. The bile salt export pump (BSEP, ABCB11), orig-
inally identiﬁed as the sister of P-glycoprotein (SPGP), is
mainly responsible for bile acid transport at the canalicular
membrane [17]( Figure 1). Mutations in BSEP were ﬁrst
identiﬁed in patients with progressive familial intrahepatic
cholestasis subtype 2 (PFIC-2). The absence of functional
BSEP in the hepatic canalicular membrane and less than 1%
of normal biliary bile acid concentration found in these pa-
tients suggested that BSEP is the major canalicular bile acid
transport system [18]. Phospholipids are excreted via the
phospholipid ﬂippase MDR2 (ABCB4) (Figure 1), and the
major phospholipid in the bile is phosphatidylcholine [19,
20]. Biliary-free cholesterol secretion mediated by ABCG5/
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Figure1:Enterohepaticcirculationofthebile.Bileacidsaresynthe-
sized from cholesterol in the hepatocytes. CYP7A1 regulates the
rate-limiting step in the classic bile acid biosynthetic pathway. Bile
acids are secreted into the gallbladder via BSEP. Phospholipids
are transported via MDR2, and cholesterol is transported by the
ABCG5/G8 transporters into the bile. In the gallbladder, bile acids,
phospholipids, and cholesterol form mixed micelles to solubilize
cholesterol and to reduce bile acid toxicity. After meal intake, gall-
bladder releases bile into the small intestine where bile acids facil-
itate the absorption of dietary lipids and vitamins. At the terminal
i l e u m ,m o s to ft h eb i l ea c i d sa r er e a b s o r b e db yA S B Ti n t ot h ee n -
terocytes, and secreted intothe portal circulation via basolateralbile
acid transporters Ostα/Ostβ. At the basolateral membrane of the
hepatocytes, bile acids are taken up by the NTCP transporter for
resecretion into the gallbladder.
G8 transporters is an important route for hepatic cholesterol
elimination. Bile acids, phospholipids, and cholesterol are
three major organic solutes of the bile and once secreted,
they form mixed micelles to increase cholesterol solubility
and reducetheirtoxicitytothebileduct.Bileacidsareconju-
gated with taurine or glycine in the peroxisomes and present
asbilesalts.Theycannot crossthehepatocytemembraneand
need active transport mechanisms for cellular uptake [21].
Two bile acid transporters, Na+-dependent taurocholate
transporter (NTCP) (Figure 1) and organic anion trans-
porters (OATPs) are responsible for basolateral bile acid
transport into the hepatocytes.
In the intestine, bile salts are deconjugated, and bacterial
7α-dehydroxylase removed a hydroxy group from C-7 and
converts CA to DCA and CDCA to LCA. These secondary
bile acids are highly toxic. In the intestine lumen, bile
acids are reabsorbed mostly at the terminal ileum. Like the
hepatic basolateral uptake system, intestinal bile acid uptake
is also mainly mediated by the apical sodium-dependent
bile salt transporter (ASBT) (Figure 1)[ 22]. Once absorbed
into the enterocytes, bile acids bind the intestinal bile
acid binding protein (I-BABP) and are transported to the
basolateral membrane for secretion [23]. Recently identiﬁed
heterodimeric organic solute transporters OSTα and OSTβJournal of Lipids 3
appeared to be the major basolateral bile acid transport
system in the intestine and many other epithelial cells
(Figure 1)[ 24]. This is supported by studies showing that
over-ex-pression ofOSTα and OSTβ in mice enhanced baso-
lateral eﬄux of taurocholate, while mice lacking ostα showed
marked decreases in intestinal bile acid absorption, serum
bile acid concentration, and bile acid pool size.
4.RegulationofBile AcidSynthesis
4.1. Bile Acid Feedback Regulation of Its Own Synthesis. It
is clear that bile acid synthesis is mainly controlled via
the transcriptional regulation of the CYP7A1 gene [11]. It
is well established that the CYP7A1 gene is repressed by
bile acids. This bile acid feedback repression mechanism
allows the liver to eﬃciently increase or decrease bile acid
synthesis in response to changes in bile acid levels and thus
to maintain a constant bile acid pool. It is thought that bile
acid feedback inhibition of CYP7A1 is mediated by the bile
acid-activated nuclear receptor farnesoid X receptor (FXR)
in the hepatocytes and the enterocytes (Table 1). It was
ﬁrst discovered that hepatic FXR induced a negative nuclear
receptor small heterodimer partner (SHP), which interacts
with and represses the transcriptional activator liver-related
homologue-1 (LRH-1) that binds to the CYP7A1 gene pro-
moter and thus inhibit CYP7A1 transcription [25]. However,
the repression of CYP7A1 by bile acids and FXR agonist in
SHP-deﬁcient mice implies that FXR-SHP-LRH-1 cascade is
not the only pathway mediating bile acid feedback inhibition
of CYP7A1 and redundant pathways also exist [26, 27].
More recently, FXR was shown to induce intestine ﬁbroblast
growth factor 15 (FGF15) which may act as an endocrine
hormone to repress CYP7A1 gene transcription via ERK sig-
nalingactivation[28].DirectinfusionofrecombinantFGF15
into mouse blood circulation or overexpression of FGF15
in mouse livers via an adenovirus expression vector caused
marked repression of CYP7A1 mRNA expression. The
identiﬁcation of an intestine-initiated endocrine mechanism
in mediating bile acid feedback regulation is consistent with
the fact of intestine being the major organ for bile ac-
id reabsorption and retention. Such ﬁnding also provides an
explanation to a long observed phenomenon that intraduo-
denal, but not intravenous, infusion of taurocholic acid
repressed CYP7A1 mRNA expression in rats [29]. In mice
lacking functional Ostα/Ostβ, bile acid transport to the liver
was reduced and bile acids accumulated in the intestine.
Interestingly, these mice showed increased intestine FGF15
expression and reduced liver CYP7A1 mRNA and total
bile acid pool [30]. Furthermore, intestine-speciﬁc FXR
knockout, but not liver-speciﬁc FXR knockout, prevented
GW4064 repression of liver CYP7A1 gene expression in
mice [31]. These studies collectively suggest that intestine
FXR plays a dominant role in mediating bile acid feedback
repression of bile acid synthesis. Unfortunately, data on
detection of the presence of FGF15 protein in the mouse
circulation is lacking, and such evidence is needed in order
to eventually establish the endocrine mechanism of feedback
regulationofbileacidsynthesis. HumanFGF19shares ∼51%
amino acid sequence identity with mouse FGF15 and is
considered as the mouse FGF15 orthologue. FGF19 has been
shown to repress CYP7A1 in human hepatocytes [32]. In
contrast to FGF15 that is not detectable in mouse livers and
circulation, FGF19 mRNA is detectable in human livers and
human hepatocytes [32, 33]. FGF19 protein is present in
human circulation [34]. In human hepatocytes, FGF19 is
highly inducible by bile acids or FXR agonists [32]. Since
adenovirus-mediated overexpression of FGF15 in mouse
liver has been shown to repress CYP7A1,i ti sl i k e l yt h a tb i l e
acid accumulation in human liver may induce FXR/FGF19
pathway to repress CYP7A1 in an autocrine manner [32].
Previous studies from us and others showed that bile acids
were able to activate FXR-independent cell signaling path-
ways to repress the CYP7A1 gene [35, 36]. We recently
showed that feeding FXR knockout mice a cholic acid-con-
taining diet still repressed CYP7A1 despite the absence of
FGF15 or SHP induction [6]. These results indicate that
in response to super-physiological concentrations of bile
acids, redundant pathways are stimulated to repress bile acid
synthesis. These pathways ensure prompt repression of de
novobileacidsynthesis inresponsetoelevatedbileacidlevels
in the liver and/or the intestine.
4.2. Nutrient Eﬀects on Hepatic Bile Acid Synthesis. Despite
the majority of studies being focused on the regulatory roles
of bile acids in nutrient metabolism, there is also evidence
that nutrition could directly regulate bile acid synthesis. In
humans, CYP7A1 activity, as determined by a serum surro-
gate 7alpha-hydroxycholest-4-en-3-one (C4), increases dur-
ingpostprandialperiodsduringthedayanddecreasesduring
fastingandatnight[37].Ametabolomicstudyalsoidentiﬁed
bile acids as the most markedly elevated metabolites in hu-
man sera after an oral glucosechallenge in patients with nor-
mal glucose tolerance, but this response was blunted in
patients with impaired glucose tolerance [38]. Since post-
prandial period is the highly active in metabolism and hu-
mans undergo fasting-to-feeding cycles a few times a day,
these observations could indicate an important link between
bile acid synthesis and postprandial nutrient absorption and
metabolism. Nutrient-activated signaling such as those by
glucose or insulin is by far the most important signaling that
regulates postprandial metabolism. Using primary human
hepatocytes, we have demonstrated that insulin rapidly in-
ducedwhile glucagonrepressed CYP7A1mRNA[39,40].We
also reported that glucose induced CYP7A1 gene transcrip-
tion via inducing histone hyperacetylation in CYP7A1 gene
chromatin [41]. Although our in vitro study provide mech-
anistic support for human observations, studies using in
vivo mouse models yielded controversial results. It has been
shown that PGC-1α acts as a coactivator of HNF4α and
induces CYP7A1 during fasting in mice [42]. Furthermore,
CYP7A1 mRNA was induced in STZ-treated type-I diabetic
rats lacking insulin secretion [43], which has led to the
speculationthatinsulinmayrepress CYP7A1geneinrats.On
the otherhand, more recent studiesseem tobe contradictory
to these early observations. First, mouse CYP7A1 mRNA ex-
pression peaked during the early dark cycle when food in-
take was the most active [44, 45]. Furthermore, restricted
feeding during light cycles shifted the peak of CYP7A14 Journal of Lipids
Table 1: FXR target genes and their function and lipid and glucose metabolism.
Gene Tissue Regulation Function
Bile acid metabolism
CYP7A1 liver down Encodes the rate-limiting enzyme in classic bile acid synthetic pathway
BSEP liver up Rate-limiting step in canalicular bile acid transport into the gallbladder
NTCP liver down Basolateralbile acid uptake into the hepatocytes
OSTα/β intestine up Enterocyte basolateralbile acid secretion into the portal blood
I-BABP intestine up Intracellular bile acid transport
FGF15/19 intestine up Bile acid synthesis inhibition
SHP liver up Bile acid synthesis inhibition
Glucose metabolism
PEPCK liver up Gluconeogenesis
FGF15/19 intestine up Stimulates glycogen synthesis, repress gluconeogenesis
Insulin pancreas up Glucose metabolism
Cholesterol metabolism
ApoA1 liver down HDL metabolism
LDLR liver down LDL uptake
ABCG5/G8 liver up Biliary-free cholesterol secretion
SRB1 liver up Hepatic HDL uptake, biliary cholesterol secretion
PCSK9 liver down Induces LDL receptor degradation
Fatty acid metabolism
ApoC II liver up LPL activator
ApoC III liver down LPL inhibitor
SREBP1 liver down Lipogenesis
mRNA expression from dark cycles to light cycles [44]. Such
evidenceseemstoimplythatliverbileacidsynthesis andliver
metabolism are coordinately controlled. Further studies are
necessary to determine if nutritional regulation of bile acid
synthesis may play a role in metabolic homeostasis during
fasting to refeeding cycles.
5.BileAcid RegulationofGlucoseMetabolism
5.1.FXRandGlucoseMetabolism. Diabetesisassociatedwith
impaired peripheral glucose clearance and increased hepatic
glucose production during fasting, which lead to postpran-
dialandfasting hyperglycemia.Initialevidencethatbileacids
may regulate glucose metabolism came from studies show-
ing that FXR agonist induced phosphoenolpyruvate Carbox-
ykinase (PEPCK) mRNA expression (Table 1)a n dg l u c o s e
output in human and rat hepatocytes [46]. Treating mice
with an FXR agonist also induced hepatic PEPCK mRNA ex-
pression in mice in vivo [46]. A FXR binding site has been
identiﬁed in the promoter of PEPCK gene. In contrast,
later studies carried out in fxr knockout mice revealed that
FXR-deﬁcientmice had insulin resistance and hyperglycemia
phenotypes. Administration of a FXR agonist GW4064 de-
creased serum glucose, increased liver glycogen, and im-
proved insulin sensitivity in diabetic db/db mice [7, 8]. A
number of recent studies showed that bile acids and FXR
repressed hepatic PEPCK and G6Pase gene expression and
thus liver gluconeogenesis. In this case, it is shown that bile
acids may induce the repressor SHP, which inhibits PEPCK
via inhibiting C/EBP [47], FoxO1 [48], and Glucocorticoid
receptor [49]. Although these liver eﬀects of FXR activation
may prevent fasting hyperglycemia, it does not suﬃciently
explain the increased insulin sensitivity and glucose disposal
in FXR agonist-treated mice as determined by glucose and
insulin tolerance tests. In a similar study, Cariou et al. used
hyperinsulinemic euglycemic clamp and demonstrated that
FXR-deﬁciency is associated with decreased whole-body glu-
cose disposal, suggesting a role of FXR in regulating periph-
eral glucosemetabolism [50].FXRisnotexpressed inmuscle
but is expressed in white adipose at a very low level. It is
noticed that fxr−/− mice had smaller adipocytes, and FXR
agonist GW4064 treatment increased adipose diﬀerentiation
and insulin-dependent glucose uptake in 3T3-L1 cells in
vitro. Another study suggests that FXR agonist INT747 in-
duced adipose diﬀerentiation via inducing the expression
of adipocyte-related genes including C/EBPα and PPARγ
[51]. In addition to a role of FXR in adipose, two recent
studies provided additional mechanism by which FXR may
regulate peripheral glucose homeostasis. These studies re-
vealed that FXR is also expressed in pancreatic β cells and
positively regulates glucose-dependent insulin secretion
[52]. It is suggested that FXR activation stimulates insulin
gene transcription. On the other hand, FXR activation is
associated with increased AKT phosphorylation and GLUT2
translocation to the cell membrane and thus enhances glu-
cose uptake into pancreatic β cells and glucose-dependent
insulin secretion. Intestine is another major FXR expressing
tissue. A recent study showed that FGF15/19, expressed in
the intestine and secreted into the blood circulation, acts as a
postprandial factor that promotes glycogen synthesis, which
may be an important mechanism controlling postprandial
glucose metabolism [53]. It has been shown that serum
FGF19 increases during postprandial period in humans, pre-
sumably due to increased bile acid signaling [34]. Therefore,
identiﬁcation of the regulatory role of FGF15/19 in post-
prandial glycogen synthesis provides a novel link between
bile acid signaling and glucose metabolism. In addition to
the nuclear receptor FXR-mediated eﬀects, bile acids have
beenshowntodirectlyactivatehepaticAKTviaaGαi proteinJournal of Lipids 5
coupledreceptor signaling pathway, which stimulated hepat-
ic glycogen synthesis [54]. Recently, it was further demon-
strated that bile acid activation of the Gαi-AKT signaling
cascade was involved in the bile acid induction of FXR and
SHP and downregulation of gluconeogenic gene expressions
in the liver [55]. In summary, these studies suggest that bile
acid regulation of hepatic glucose metabolism involves com-
plex crosstalk between FXR-dependent pathways and FXR-
independent signaling pathways.
5.2. TGR5 and Glucose Metabolism. Bile acids also activate
a cell surface G-protein coupled receptor TGR5, which is
mainly expressed in the intestine, brown adipose, white adi-
pose,and gallbladder. LowlevelsofTGR5expression hasalso
been detected in liver and skeletal muscle. Upon activation,
TGR5 leads to intracellular cAMP production and PKA acti-
vation. Based on the ability to induce cellular cAMP produc-
tion, taurolithocholic acid (TLCA) and LCA show highest
potency in activating TGR5 with EC50 of 0.33 and 0.53μM,
respectively, while DCA, CDCA, and CA (in rank order)
activate TGR5 at higher 1–8μM concentrations [56]. It is
suggested that in brown adipocytes, bile acid activation of
TGR5-cAMP-PKA cascade results in induction of down-
stream deiodinase, fatty acid oxidation genes, and uncou-
pling proteins, which increase energy expenditure and pro-
mote weight loss [57]. As increased free fatty acid release
and cytokine production associated with obesity clearly con-
tribute to the development of insulin resistance, bile acids/
TGR5 regulation of weight loss certainly could play a role in
regulating glucose homeostasis. However, studies in tgr5−/−
mice showed that neither under chow condition nor under
high fat diet feeding condition did tgr5−/− develop obesity
or hyperglycemia [58]. The high fat diet feeding eﬀect on
insulin sensitivity, as determined by insulin tolerance tests,
also seemedtobe gender-speciﬁcintgr5−/− mice,with male
showing impaired, but female showing improved insulin
sensitivity [58]. The most potent endogenous ligand for
TGR5 is TLCA. TLCA is highly toxic and once synthesized,
is rapidly metabolized in the intestine and the liver. Under
physiological conditions, liver eﬃciently extracts bile acids
from the portal circulation, and bile acid concentration in
the systemic circulation is very low. Because these primary
and secondary bile acids activate TGR5 at a higher EC50,i t
is possible that TGR5 is not activated by physiological con-
centration of circulating bile acids outside of the entero-
hepatic system. Thus, opposing to the clear pharmacolog-
ical beneﬁts of TGR5 activation, the physiological role of
TGR5 in mediating bile acid signaling control of metabolic
homeostasis needs to be further investigated. In addition to
brown adipose, intestine is another major TGR5 expressing
tissue. Using an enteroendocrine cell line STC-1, Katsuma
et al. ﬁrst demonstrated that bile acids stimulate glucagon
like peptide-1 (GLP-1) production via TGR5 activation [59].
The pharmacological signiﬁcance of this pathway was then
demonstrated by a detailed study carried out by Thomas
et al. [60]. These authors showed that administration of a
potent TGR5 agonist INT777 raised intracellular ATP/ADP
ratio and calcium inﬂux, which leads to enhanced GLP-1
secretion from the intestine. GLP-1 is known to promote
insulin secretion and thus regulate glucose homeostasis. Be-
cause GLP-1 mimetics and receptor agonists are currently
under clinical development and have shown promise in im-
proving glucose homeostasis in diabetes, bile acid-based
TGR5 agonists may be a potential therapeutic to stimulate
GLP-1 secretion in diabetic patients [61].
In contrast to these studies, bile acid sequestrants, which
remove bile acids from the body by binding to bile acids in
the intestine and prevent bile acids from being reabsorbed,
have been shown to improve insulin sensitivity and lower
fasting glucose in both men and several diﬀerent experimen-
tal models [62]. Two studies conducted in rats have so far
suggested that bile acid sequestrants may improve insulin
sensitivity by increasing GLP-1 release [63, 64]. Althoughthe
molecularmechanism isstill notclear,bothstudiessuggested
that such eﬀect is likely bile acid receptor-independent. This
is because both studies showed that administration of bile
acid sequestrants signiﬁcantly lowered serum bile acid levels,
which was associated with decreased FXR activation in the
liverandtheintestine.Furthermore,itisshownthatblocking
intestine bile acid transport using SC-435, an apical sodium-
dependent bile acid transport inhibitor, also lowered serum
bile acid levels, but did not modulate insulin sensitivity or
GLP-1 secretion. Thus, it is likely that bile acid sequestrants
exert its eﬀectby directly modulating cellularsignaling in the
intestine rather than by altering circulating bile acid levels or
modulating bile acid pool.
6.Bile Acidsand LipidMetabolism
6.1.BileAcidsand CholesterolMetabolism. Ithasbeenknown
for a long time that preventing bile acid reabsorption in the
intestine bybileacidsequestration increases hepaticCYP7A1
a n db i l ea c i ds y n t h e s i s[ 65]. The resulting increase in hepatic
cholesterol catabolism caused compensatory induction of
LDL receptor (LDLR) and LDL cholesterol (LDL-C) uptake.
Because of the activation of this liver pathway, cholestyra-
mine has been used to eﬀectively lowering serum cholesterol
in human patients. Paradoxically, activation of FXR by its
potent agonists, which repress hepatic bile acid synthesis,
also decreased serum cholesterol in animal models [7]. In
wild-type mice, activation of FXR is mainly associated with
a reductionofHDL-C,while inhypercholesterolemic animal
models, activation of FXR decreases both LDL-C and HDL-
C. In vitro, FXR was shown to induce LDLR expression
and repress PCSK9, an LDLR inhibitor [66]. However,
activation of FXR still signiﬁcantly decreased serum non-
HDL cholesterol in ldlr−/− mice [67]. Furthermore, CDCA
administration has been shown to raise serum LDL-C levels
in humans. It remains to be determined whether activation
of FXR will provide beneﬁts in lowering LDL-C in men.
FXR agonists have been shown to prevent atherosclerosis
in various experimental models [68]. SerumHDLtransports
cholesterolfromperipheraltissuestotheliverforelimination
and thus plays a critical role in reverse cholesterol transport
and the development of atherosclerosis. However, the role
of FXR in regulating HDL metabolism is still under debate
because FXR inhibits the hepatic production of apolipopro-
tein A1 (ApoAI), a key structural component of HDL, and6 Journal of Lipids
activation of FXR is associated with decreased serum HDL
[69]. Nevertheless, a recent study showed that activation
of FXR promotes reverse cholesterol transport in mice by
inducing hepatic expression of scavenger receptor B1 (SR-
B1) [70], which is suggested to play a role in both hepatic
uptake of HDL-C and biliary secretion of free cholesterol
[71]. A FXR binding site has been identiﬁed in the SR-B1
gene promoter [72]. In a recent study, we demonstrated
that stimulating de novo bile acid synthesis by transgenic
expression of a CYP7A1 gene in mouse liver prevented diet-
induced hypercholesterolemia [6]. Diﬀerent from CA feed-
ing or FXR agonist administration, Cyp7a1-tg mice showed
both increased hepatic cholesterol catabolism and bile acid
signaling. Using this model, we demonstrated that bile acid
activation of FXR induces hepatic expression of ABCG5 and
ABCG8 through a common FXRE, which promoted bili-
ary-free cholesterol secretion and fecal cholesterol loss. It is
well known that cholesterol activation of LXR only induces
mouse, but not human CYP7A1 gene expression [73]. We
also showed that cholesterol/LXR signaling only induced
ABCG5 and ABCG8 in mice, but not in primary human
hepatocytes[6].Thesestudiessuggestthatuponhepaticcho-
lesterol accumulation, LXR may stimulate cholesterol catab-
olism or biliary cholesterol secretion in mouse livers, but not
human livers. Thus, it is possible that bile acid/FXR/ABCG5/
G8 pathway plays a more important role in maintaining
hepaticcholesterolhomeostasisinresponse toincreasedcho-
lesterol levels in humans.
6.2. Bile Acids and Fatty Acid Metabolism. It has been known
for a long time that serum bile acid and serum triglycer-
ides are inversely correlated, suggesting that bile acid nega-
tively regulates serum triglycerides [74, 75]. Current studies
suggest that bile acids may lower serum triglycerides by re-
pressing both hepatic triglyceride production/secretion and
stimulating serum triglyceride clearance. In the liver, it is
shown that bile acid activation of FXR repressed LXR-
induction of SREBP-1 and its target genes in de novo lipo-
genesis by inducing the repressor SHP, which not only de-
creased hepatic fat accumulation, but also led to reduced he-
patic VLDL secretion [76]. One study showing both LXR-
dependent and FXR-dependent induction of hepatic lipoge-
nesis by bile acid sequestrants administration supported this
conclusion [68]. The ﬁnding that FXR represses microsomal
triglyceride transfer protein (MTP) and thus hepatic VLDL
secretion seems to provide additional support that the
FXR/SHP pathway reduces hepatic triglyceride output [77].
Genetic knockout of shp in ob/ob mice increased MTP and
VLDL secretion [78]. Diabetes and obesity are associated
with increased hepatic VLDL output. Both increased fatty
acid supply to the liver and hepatic insulin resistance may be
involved. On the other hand, there are also studies showing
that hepatic VLDL secretion was impaired in diabetic mouse
models despite increased triglyceride output [79]. Further-
more, increased VLDL secretion in shp knockout mice
seemed to be beneﬁcial in reducing hepatic fat accumulation
in ob/ob mice [78]. Thus, the bile acid regulation of hepatic
VLDL secretion and its in vivo signiﬁcance seem to be com-
plexand maydependonthe experimental conditions.Serum
triglyceride is cleared after VLDL-triglyceride is hydrolyzed
by lipoprotein lipase (LPL) and subsequently taken up by
the peripheral tissues. It has been reported that obesity
and diabetes are also associated with impaired peripheral
triglyceride clearance, contributing to diabetic hypertriglyc-
eridemia. Activation of FXR has been shown to induce
apolipoprotein CII (ApoCII), which is an LPL activator,
and repress apolipoprotein CIII (ApoCIII), which is an LPL
inhibitor in the liver [80, 81]. Increasing ApoCII or decreas-
ing ApoCIIIstimulates LPL tohydrolyze triglyceridescarried
by VLDL, thus accelerates serum VLDL clearance upon FXR
activation.
7.Conclusion
Extensive investigations conducted in the past decade have
shown thatbile acidsare important regulators ofglucoseand
lipid metabolism. The identiﬁcation of bile acid-activated
nuclear receptor FXR and cell surface G protein coupled
receptorTGR5 has signiﬁcantly advanced ourunderstanding
on how bile acid signaling regulates cellular metabolism
in physiological and diseased conditions. The identiﬁcation
of these regulatory mechanisms also provided molecular
basis for developing bile acid receptor agonists and receptor
antagonists for treating human metabolic diseases. On the
other hand, conﬂicting studies in the ﬁeld are present, which
not only reﬂects the complex nature of the bile acid signaling
in regulation ofwhole body metabolism, butalso implies the
diﬀerence between physiological role and pharmacological
role of bile acid signaling in metabolic control. Furthermore,
studies that focus on the regulation of bile acid metabolism
in diseased conditions, especially obesity and diabetes, are
still insuﬃcient. Future advances in the ﬁeld are needed
to improve our understanding in the bile acid control of
metabolism, which is also critical in developing better drug
therapies for the treatment of metabolic disorders.
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